Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11290405 | 1.00 | LMNA (0.77) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| SCHEMBL11295543 | 0.99 | LMNA (0.75) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| SCHEMBL11292589 | 0.92 | LMNA (0.65) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| Rac-Etomoxir SCHEMBL681359 | 0.87 | ABCB11 (1.00) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| SCHEMBL954683 | 0.87 | ABCB11 (1.00) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| Etomoxir SCHEMBL49075 | 0.87 | ABCB11 (1.00) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| Rac-Etomoxir SCHEMBL15256787 | 0.87 | ABCB11 (1.00) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| Etomoxir SCHEMBL12813827 | 0.86 | MAPT (0.98) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| Etomoxir SCHEMBL5883664 | 0.86 | MAPT (0.98) | LMNAABCB11MAPTMAPK1ALDH1A1 | |
| Rac-Etomoxir SCHEMBL2141141 | 0.85 | MAPT (0.95) | LMNAABCB11MAPTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC | 2020-10-22 | — | — | US | claimed |
| WO-2017161205-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC (US) | 2017-09-21 | — | — | WO | claimed |
| WO-2014018801-A1 | DIAGNOSIS AND TREATMENT OF CANCER USING DIFFERENTIALLY EXPRESSED STARVATION MARKERS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-01-30 | — | — | WO | claimed |
| WO-2013071029-A1 | METHODS AND PRODUCTS FOR GENERATING OILS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2012135632-A2 | METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-04 | — | — | WO | claimed |
| EP-2486140-A2 | COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS | Regents of the University of Colorado (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011043806-A2 | COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-04-14 | — | — | WO | claimed |
| US-20110078946-A1 | COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2011-04-07 | — | — | US | claimed |
| EP-1275390-B1 | Medicament for treatment of heart failure | WOLF HORST P O (DE) | 2005-11-02 | — | — | EP | claimed |
| US-5739159-A | Medicaments for the treatment of cardiac insufficiency | WOLF HORST (DE) | 1998-04-14 | — | — | US | claimed |
| EP-0231367-B1 | USE OF OXIRANCARBOXYLIC ACIDS FOR THE TREATMENT OF HYPERLIPEMIA | Wolf, Horst P.O., Dr. (DE) | 1991-07-24 | — | — | EP | claimed |
| US-20200330400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC | 2020-10-22 | — | — | US | disclosed |
| US-10041096-B2 | Methods and products for generating oils | TEXAS A & M UNIV SYS (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017161205-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-08-20 | — | — | US | disclosed |
| WO-2005107801-A2 | SYSTEMS AND METHODS FOR TREATING HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES, WITH A COMBINATION OF FATTY ACID METABOLISM INHIBITORS AND GLYCOLYTIC INHIBITORS AND/OR UCP AND/OR FAS ANTIBODIES | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005070126-A2 | METHODS AND COMPOSITIONS FOR TREATING HUMAN DISEASES AND WOUNDS WITH UCP AND FAS INHIBITORS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050020682-A1 | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-01-27 | — | — | US | disclosed |
| WO-2004111199-A2 | SYSTEMS AND METHODS FOR TREATING HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES AND WOUNDS, WITH FATTY ACID METABOLISM INHIBITORS AND/OR GLYCOLYTIC INHIBITORS | UNIVERSITY OF COLORADO SYSTEM TECHNOLOGY (US) | 2004-12-23 | — | — | WO | disclosed |
| US-5739159-A | Medicaments for the treatment of cardiac insufficiency | WOLF HORST (DE) | 1998-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | CPT1B, CPT2, CPT1A | LMNA 1667/4885ABCB11 1461/4885MAPT 2554/4885 |
| US-20050020682-A1 | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors | FASN, G6PD, HK2 | LMNA 4726/4885ABCB11 4224/4885MAPT 3096/4885 |
| US-10041096-B2 | Methods and products for generating oils | LIPE, FASN, LIPC | LMNA 4267/4885ABCB11 672/4885MAPT 4545/4885 |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | BECN1, G6PD, VHL | LMNA 3405/4885ABCB11 2781/4885MAPT 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.